Table 1.
Summary of immunotherapy studies in acral and mucosal metastatic melanoma.
| Melanoma subtype | Studya | Patients (N) | Treatment (line of therapy) | Response rate (%) | Median survival notes (months) |
|---|---|---|---|---|---|
| Acral | Shoushtari et al (63) | 25 | Anti-PD-1 (mixed) | 32 | PFS: 4.1 OS: 31.7 |
| Klemen et al (62) | 22 | Anti-CTLA-4, anti-PD-1, and/or anti-PD-L1 (mixed) | Not reported | PFS: not reported OS: 17 |
|
| Ogata et al (64) | 38 | Anti-PD-1 (mixed) | 21 | PFS: 3.6 OS: 21 |
|
| Namikawa et al (65) | 7 | Ipilimumab + Nivolumab (1st line) | 42.9 | PFS: not reported OS: not reported |
|
| Nakamura et al (67) | 193 | Anti-PD-1 (mixed) | 16.6 | PFS: 3.5 OS: 18.1 |
|
| Si et al (68) | 39 | Pembrolizumab (2nd line) | 15.8 | PFS: 2.8 months (aggregate) OS: 12.1 (aggregate) |
|
| Mucosal | Shoushtari et al (63) | 35 | Anti-PD-1 (mixed) | 23 | PFS: 3.9 OS: not reported |
| Klemen et al (62) | 38 | Anti-CTLA-4, anti-PD-1, and/or anti-PD-L1 (mixed) | Not reported | PFS: not reported OS: 18 |
|
| Ogata et al (64) | 59 | Anti-PD-1 (mixed) | 15.2 | PFS: 3 OS: 20.1 |
|
| Namikawa et al (65) | 12 | Ipilimumab + Nivolumab (1st line) | 33.3 | PFS: not reported OS: not reported |
|
| Si et al (68) | 15 | Pembrolizumab (2nd line) | 12.5 | PFS: 2.8 months (aggregate) OS: 12.1 (aggregate) |
|
| D’Angelo et al (69) | 86 | Anti-PD-1 (mixed) | 23.3 | PFS: 3 OS: not reported |
|
| 35 | Ipilimumab + Nivolumab (1st line) | 37.1 | PFS: 5.9 OS: not reported |
||
| Nakamura et al (71) | 263 | Anti-PD-1 (1st line) | 26 | PFS: 5.9 OS: 20.4 |
|
| 66 | Ipilimumab + Nivolumab (1st line) | 29 | PFS: 6.8 OS: 20.1 |
||
| Umeda et al (72) | 115 | Anti-PD-1 (1st line) | 26 | PFS: 6.2 OS: 19.2 |
|
| 42 | Anti-PD-1 + radiotherapy (1st line) | 27 | PFS: 6.8 OS: 23.1 |
||
| 56 | Anti-PD-1 + anti-CTLA-4 + radiotherapy (1st line) | 28 | PFS: 5.8 OS: 31.7 |
||
| 12 | Anti-PD-1 + anti-CTLA-4 (1st line) | 25 | PFS: 3.5 OS: 19.8 |
Italic = trial; all others were retrospective studies.